BUFFALO, N.Y., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies ...

Although some data exist on the economic burden of mBC, limited data are available on the specific costs of care with IV paclitaxel and IV nab-paclitaxel treatment. 14,16 This observational ...

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies ...

Background: Oblimersen (OBL), temozolomide (TMZ), and albumin-bound paclitaxel (ABP) are synergistic in melanoma cell lines. We recently reported promising results with this regimen in 18 patients ...

The need for IV infusion also means patients have to go to a medical center to be treated, limiting global access to this medicine. An oral paclitaxel was the team's ultimate test of their sol ...

Results from a Phase 3 clinical trial comparing Athenex's (ATNX -17.4%) oral paclitaxel (and oral absorption technology encequidar) to the intravenous ...

--Athenex, Inc.,, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced ...

--Athenex, Inc.,, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today ...

The need for IV infusion also means patients have to go to a medical center to be treated, limiting global access to this medicine. An oral paclitaxel was the team's ultimate test of their sol ...

* Data presented at SABCS indicates benefits of oral paclitaxel and encequidar (oral paclitaxel) versus IV paclitaxel (IVP) on Progression-Free Survival (PFS) and on Overall Survival (OS), which ...

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of ...